Abstracts tagged "mycophenolate mofetil"

Abstract Number: 317 • 2019 ACR/ARP Annual Meeting
Improving Adherence to Pregnancy Screening in Patients on Teratogenic Medications Using an Electronic Medical Record Alert System: A Quality Improvement Initiative
Vy Do¹, MaiLan Nguyen ¹, Keiji Akamine ², Julie Fuller ¹, Lorien Nassi ¹, Tracey Wright ³ and Katie Stewart ¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Tokyo Metropolitan Children's Medical Center, Tokyo, Japan, ³University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX
Background/Purpose: Mycophenolate is widely prescribed in the rheumatology setting. However, usage of mycophenolate during the first trimester of pregnancy is associated with an increased risk…
Abstract Number: 794 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil for the Treatment of Severe or Methotrexate-refractory Juvenile Localized Scleroderma
Laura Saggioro ¹, Giorgia Martini ¹, Roberta Culpo ¹, Alessandra Meneghel ¹ and Francesco Zulian², ¹Dept. of Woman's and Child's Health, University of Padua, Italy, Padua, Italy, ²Department of Woman and Child Health, University of Padua, Italy, Padova, Italy
Background/Purpose: Juvenile Localized Scleroderma (JLS), includes a number of conditions characterized by skin thickening with varying degree of severity. Many patients, particularly those with the…
Abstract Number: 1146 • 2019 ACR/ARP Annual Meeting
Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity
Prathima Anandi ¹, Alyson Dickson ², Vivian Kawai ², C. Michael Stein ² and Cecilia Chung³, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: Randomized clinical trials have reported that 56-68% of patients with lupus nephritis treated with mycophenolate mofetil (MMF) respond to therapy, and a randomized clinical…
Abstract Number: 1649 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Holly LeClair ², Philip Clements ², Daniel Furst ⁴, Robert Elashoff ² and Dinesh Khanna ⁵, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of California, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). The majority of studies investigating novel therapies for…
Abstract Number: 2344 • 2019 ACR/ARP Annual Meeting
Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Jonathan Amos¹, Jennifer Kendall ¹, Robyn Moran ², Megan Krause ³, Paul Schmidt ⁴, Chase Hall ⁵, Mark Hamblin ⁶ and Mehrdad Maz ⁷, ¹University of Kansas Medical Center, Division of Rheumatology, KANSAS CITY, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Kansas, KANSAS CITY, KS, ⁴University of Kansas Medical Center, Division of Rheumatology, Kansas City, ⁵University of Kansas Medical Center, Division of Pulmonary and Critical Care, KANSAS CITY, ⁶University of Kansas Medical Center, Division of Pulmonary and Critical Care, Kansas City, KS, ⁷The University of Kansas Medical Center, KANSAS CITY, KS
Background/Purpose: Interstitial lung disease (ILD) as an extra-articular manifestation of rheumatoid arthritis (RA) leads to significant morbidity and mortality. As data is limited, this study…
Abstract Number: 2837 • 2018 ACR/ARHP Annual Meeting
Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients
Samantha Slight-Webb¹, Joel M. Guthridge¹, Eliza Chakravarty¹, Hua Chen¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Stanford University, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Mycophenolate mofetil (MMF) is a commonly used medication to treat major organ involvement in SLE, specifically in patients with lupus nephritis. The safety and…
Abstract Number: 2583 • 2017 ACR/ARHP Annual Meeting
Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Priya Prakash¹, Mark Tratenberg², Slavica Bobic³, Rui Zhang⁴, Kirk Sperber⁵, Amy Wasserman⁶ and Julia Ash⁷, ¹Medicine-Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY, ²New York Medical College / Westchester Medical Center, valhalla, NY, ³Medicine-Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ⁴Medicine -Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ⁵New York Medical College / Westchester Medical Center, Valhalla, NY, ⁶Medicine - Rheumatology, New York Medical College / Westchester Medical Center, VALHALLA, NY, ⁷Medicine -Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY
Background/Purpose: MMF suppresses immune function by inhibiting T cell dependent and independent humoral immune responses. This study investigates the humoral immune response to the PPSV23…
Abstract Number: 2152 • 2017 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Treatment with or without a Calcineurin Inhibitor in Resistant Inflammatory Myopathy
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose : Patients with polymyositis (PM) and dermatomyositis (DM) refractory to glucocorticoid therapy have been treated with a variety of immunosuppressants including mycophenolate mofetil (MMF)…
Abstract Number: 5L • 2016 ACR/ARHP Annual Meeting
Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study
Mary Anne Dooley¹, William Pendergraft III², Ellen M. Ginzler³, Nancy J. Olsen⁴, James Tumlin⁵, Brad H. Rovin⁶, Frédéric A. Houssiau⁷, David Wofsy⁸, David A. Isenberg⁹, Neil Solomons¹⁰, Robert Huizinga¹¹ and AURA Study Group, ¹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²Kidney Center, University of North Carolina, Chapel Hill, NC, ³Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ⁴Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ⁵Nephrology, University of Tennessee College of Medicine, Chattanooga, TN, ⁶Ohio State University Medical Center, Columbus, OH, ⁷Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁸Rheumatology, University of California, San Francisco, San Francisco, CA, ⁹Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ¹⁰Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ¹¹Clinical Affairs, Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI intended for use in the treatment of autoimmune diseases such as lupus nephritis. VCS’s unique structure allows for…
Abstract Number: 418 • 2016 ACR/ARHP Annual Meeting
Discrepancy in Reported and Actual Rates of Counseling on Teratogenicity and the Need for Contraception When Initiating Mycophenolate in Women of Childbearing Age
Jenna Thomason¹ and Alison Bays², ¹Medicine, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Many women of childbearing potential with autoimmune diseases require terotogenic medications, such as mycophenolate. On October 29, 2007 the FDA deemed mycophenolate a pregnancy…
Abstract Number: 762 • 2016 ACR/ARHP Annual Meeting
Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins
Venkat Reddy¹, Lina Martínez-Estupiñán², David A. Isenberg³, Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College Hospital, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: B cell depletion therapy based on rituximab is a therapeutic option for refractory disease in patients with Systemic Lupus Erythematosus (SLE). Hypogammaglobulinemia can be…
Abstract Number: 782 • 2016 ACR/ARHP Annual Meeting
Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review
Claudia Mendoza Pinto^1,2, Carmelo Pirone³, Ben Parker⁴ and Ian N. Bruce⁵, ¹Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Rheumatology Unit, Sapienza University of Rome, Department of Internal Medicine and Medical Specialties,, Rome, Italy, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁵Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Mycophenolate mofetil (MMF) is widely used in the treatment of SLE however little is known about factors that may predict response or other outcomes…
Abstract Number: 824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Donald P. Tashkin², Ning Li³, Michael Roth⁴, Dinesh Khanna⁵, Anna-Maria Hoffmann-Vold⁶, Philip J. Clements⁴, Daniel E. Furst¹, Robert Elashoff⁷ and Scleroderma Lung Study II Group, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶Oslo University Hospital, Oslo, Norway, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function and dyspnea in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).1 While treatment with…
Abstract Number: 1393 • 2016 ACR/ARHP Annual Meeting
Mycophenolic Acid Pharmacokinetics in Childhood-Onset Systemic Lupus Erythematosus Patients of Hispanic Ethnicity in a Single Center
Anna Carmela Sagcal-Gironella¹, Marietta De Guzman¹, Daping Zhang², Lorita Agu² and Diana Chow², ¹Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX
Background/Purpose: Mycophenolic acid (MPA) is the biologically active metabolite of mycophenolate mofetil (MMF), a widely used immunosuppressant in the treatment of childhood-onset systemic lupus erythematosus…
Abstract Number: 3247 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial
Jessica K. Gordon¹, Eliza Pelrine², Yuo-Yu Lee³, Cynthia Magro⁴, Elana J. Bernstein⁵, Horatio F. Wildman⁶ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Pathology, Weill Cornell Medical College, New York, NY, ⁵Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, ⁶Dermatology, Weill Cornell Medical College, New York, NY
Background/Purpose: Abnormalities of B cell function are part of the pathogenesis of systemic sclerosis (SSc), and B-lymphocyte stimulator (BLyS) is increased in the serum and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].